Alice T. Shaw

Alice Shaw is a leader in the development of ALK inhibitors for lung cancer who led clinical trials establishing crizotinib, alectinib, and lorlatinib as standard treatments for ALK-positive NSCLC. Her work transformed ALK-positive lung cancer from rapidly fatal disease to one with meaningful long-term survival. Shaw now serves as CMO at Novartis.

Alice Shaw是肺癌ALK抑制剂开发的领导者，领导了确立crizotinib、alectinib和lorlatinib作为ALK阳性NSCLC标准治疗的临床试验。她的工作将ALK阳性肺癌从快速致死的疾病转变为具有有意义的长期生存的疾病。Shaw现在担任诺华的CMO。